EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glial Cells as Emerging Therapeutic Targets in Neurodegenerative Diseases: Mechanistic Insights and Translational Perspectives

Thirupathirao Vishnumukkala, Che Mohd Nasril Che Mohd Nassir iD, Zaw Myo Hein iD, Prarthana Kalerammana Gopalakrishna, Barani Karikalan, Aisyah Alkatiri, Saravanan Jagadeesan, Venkatesh R Naik iD, Warren Thomas, Mohamad Aris Mohd Moklas iD, Mohd Amir Kamaruzzaman iD

Cells · 24.09.2025 · 14 (19) · 1497

DOI: 10.3390/cells14191497 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 24.09.2025. Verfasst von Thirupathirao Vishnumukkala und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Neuroglia, Translational Research, Biomedical. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 154 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universiti Kebangsaan Malaysia (UKM).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease, multiple sclerosis, and amyotrophic lateral sclerosis share converging mechanisms of neuronal dysfunction, including protein aggregation, oxidative stress, and chronic neuroinflammation. Glial cells, once considered passive supporters, are now recognized as central drivers of these processes, offering both pathogenic triggers and therapeutic opportunities. Yet, despite compelling preclinical evidence, the translation of glial-targeted therapies into clinical success has been limited. This review provides a critical synthesis of current knowledge by examining therapeutic strategies through the lens of their translational challenges and failures. This narrative review highlights how interspecies variability of glial phenotypes, shifting neuroprotective versus neurotoxic states, limited biomarker stratification, and delivery barriers have constrained trials, such as anti-triggering receptor expressed on myeloid cells 2 (anti-TREM2) antibodies in AD and glial cell line-derived neurotrophic factor (GDNF) in PD. By analyzing these obstacles across major neurodegenerative disorders, this review argue that the next stage of glial medicine requires precision approaches that integrate stage-specific phenotyping, biomarker-guided patient selection, and innovative delivery platforms. Understanding not only what has been tried but why translation has stalled is essential to chart a roadmap for effective, disease-modifying glial therapies in the aging brain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurodegenerative DiseasesNeurogliaTranslational Research, BiomedicalHumansAnimalsBiomarkers

Stichwörter der Autor:innen

glial cellsneurodegenerationneurodegenerative diseaseneuroinflammationtherapy

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Selangor, Malaysia.
  • Human Biology Department, School of Medicine, IMU University, Bukit Jalil, Kuala Lumpur 57000, Malaysia.
  • Department of Anatomy and Physiology, School of Basic Medical Sciences, Faculty of Medicine, Universiti Sultan Zainal Abidin, Kuala Terengganu 20400, Terengganu, Malaysia.
  • Department of Basic Medical Sciences, College of Medicine, Ajman University, Ajman P.O. Box 346, United Arab Emirates.
  • Center of Medical and Bio-Allied Health Sciences Research (CMBHSR), Ajman University, Ajman, United Arab Emirates.
  • Department of Pathology, Faculty of Medicine, MAHSA University, Bandar Saujana Putra, Jenjarom 42610, Selangor, Malaysia.

ORCID-Profile: Che Mohd Nasril Che Mohd Nassir, Zaw Myo Hein, Venkatesh R Naik, Mohamad Aris Mohd Moklas, Mohd Amir Kamaruzzaman

Förderung

  • Universiti Kebangsaan Malaysia (UKM)

Zitieren

APA

Vishnumukkala, T., Che Mohd Nassir, C. M. N., Hein, Z. M., Kalerammana Gopalakrishna, P., Karikalan, B., Alkatiri, A., Jagadeesan, S., Naik, V. R., Thomas, W., Mohd Moklas, M. A., & Kamaruzzaman, M. A. (2025). Glial Cells as Emerging Therapeutic Targets in Neurodegenerative Diseases: Mechanistic Insights and Translational Perspectives. Cells, 14(19), 1497. https://doi.org/10.3390/cells14191497

Vancouver

Vishnumukkala T, Che Mohd Nassir CMN, Hein ZM, Kalerammana Gopalakrishna P, Karikalan B, Alkatiri A, et al. Glial Cells as Emerging Therapeutic Targets in Neurodegenerative Diseases: Mechanistic Insights and Translational Perspectives. Cells. 2025;14(19):1497. doi:10.3390/cells14191497

BibTeX
@article{Vishnumukkala2025,
  author = {Vishnumukkala, Thirupathirao and Che Mohd Nassir, Che Mohd Nasril and Hein, Zaw Myo and Kalerammana Gopalakrishna, Prarthana and Karikalan, Barani and Alkatiri, Aisyah and Jagadeesan, Saravanan and Naik, Venkatesh R and Thomas, Warren and Mohd Moklas, Mohamad Aris and Kamaruzzaman, Mohd Amir},
  title = {Glial Cells as Emerging Therapeutic Targets in Neurodegenerative Diseases: Mechanistic Insights and Translational Perspectives},
  journal = {Cells},
  year = {2025},
  volume = {14},
  number = {19},
  pages = {1497},
  doi = {10.3390/cells14191497}
}
Kostenlos starten →